Biomarkers of multiple sclerosis: current findings
Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized ap...
Gespeichert in:
| Veröffentlicht in: | Degenerative neurological and neuromuscular disease 2017-01, Vol.7, p.19-29 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 29 |
|---|---|
| container_issue | |
| container_start_page | 19 |
| container_title | Degenerative neurological and neuromuscular disease |
| container_volume | 7 |
| creator | Harris, Violaine K Tuddenham, John F Sadiq, Saud A |
| description | Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized approach determined by an individual patient's prognosis and treatment risks. An integral part of such therapeutic decisions will be the use of molecular biomarkers to predict disability progression, monitor ongoing disease activity, and assess treatment response. This review describes current published findings within the past 3 years in biomarker research in MS, specifically highlighting recent advances in the validation of cerebrospinal fluid biomarkers such as neurofilaments (light and heavy chains), chitinases and chitinase 3-like proteins, soluble surface markers of innate immunity, and oligoclonal immunoglobulin M antibodies. Current research in circulating miRNAs as biomarkers of MS is also discussed. Continued validation and testing will be required before MS biomarkers are routinely applied in a clinical setting. |
| doi_str_mv | 10.2147/DNND.S98936 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6053099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A531759343</galeid><sourcerecordid>A531759343</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-a82d63bb26ce6008fd85b57c8ffc70921243f764ec7b290bb7171d610f9d0c973</originalsourceid><addsrcrecordid>eNptkt9rHCEQx6WkNCHNU9_LQiAEwl1GXVftQyBN-gtC8tD2WXZdvTNx9aK7hfz39bg0vSvVBwf9zHfGmUHoHYY5wTU_v769vZ5_l0LS5hU6wJjLmZQAe1v2PjrK-R7KYgJLyt-gfVpsoJwdIPLRxaFNDyblKtpqmPzoVt5UWXuTYnb5Q6WnlEwYK-tC78Iiv0WvbeuzOXo-D9HPz59-XH2d3dx9-XZ1eTPTNZfjrBWkb2jXkUabBkDYXrCOcS2s1RwkwaSmlje10bwjErqOY477BoOVPWjJ6SG62Oiupm4wvS45pNarVXIl4ScVW6d2X4JbqkX8pRpgFKQsAqfPAik-TiaPanBZG-_bYOKUFQEuGJdCkIIe_4PexymF8j1FCGENBwziL7VovVEu2Fji6rWoumQUcyZpTQs1_w9Vdm8Gp2Mw1pX7HYeTLYelaf24zNFPo4sh74JnG1CX1uRk7EsxMKj1OKj1OKjNOBT6_Xb9Xtg_zae_AZ2ErNc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2225670108</pqid></control><display><type>article</type><title>Biomarkers of multiple sclerosis: current findings</title><source>Dove Press Free</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Harris, Violaine K ; Tuddenham, John F ; Sadiq, Saud A</creator><creatorcontrib>Harris, Violaine K ; Tuddenham, John F ; Sadiq, Saud A</creatorcontrib><description>Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized approach determined by an individual patient's prognosis and treatment risks. An integral part of such therapeutic decisions will be the use of molecular biomarkers to predict disability progression, monitor ongoing disease activity, and assess treatment response. This review describes current published findings within the past 3 years in biomarker research in MS, specifically highlighting recent advances in the validation of cerebrospinal fluid biomarkers such as neurofilaments (light and heavy chains), chitinases and chitinase 3-like proteins, soluble surface markers of innate immunity, and oligoclonal immunoglobulin M antibodies. Current research in circulating miRNAs as biomarkers of MS is also discussed. Continued validation and testing will be required before MS biomarkers are routinely applied in a clinical setting.</description><identifier>ISSN: 1179-9900</identifier><identifier>EISSN: 1179-9900</identifier><identifier>DOI: 10.2147/DNND.S98936</identifier><identifier>PMID: 30050375</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antibodies ; Biological markers ; Biomarkers ; Care and treatment ; Development and progression ; Diagnosis ; FDA approval ; Health aspects ; Inflammation ; MicroRNAs ; Multiple sclerosis ; NMR ; Nuclear magnetic resonance ; Pathogenesis ; Pathology ; Prognosis ; Proteins ; Review</subject><ispartof>Degenerative neurological and neuromuscular disease, 2017-01, Vol.7, p.19-29</ispartof><rights>COPYRIGHT 2017 Dove Medical Press Limited</rights><rights>2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Harris et al. This work is published and licensed by Dove Medical Press Limited 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-a82d63bb26ce6008fd85b57c8ffc70921243f764ec7b290bb7171d610f9d0c973</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053099/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053099/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,3862,27922,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30050375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harris, Violaine K</creatorcontrib><creatorcontrib>Tuddenham, John F</creatorcontrib><creatorcontrib>Sadiq, Saud A</creatorcontrib><title>Biomarkers of multiple sclerosis: current findings</title><title>Degenerative neurological and neuromuscular disease</title><addtitle>Degener Neurol Neuromuscul Dis</addtitle><description>Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized approach determined by an individual patient's prognosis and treatment risks. An integral part of such therapeutic decisions will be the use of molecular biomarkers to predict disability progression, monitor ongoing disease activity, and assess treatment response. This review describes current published findings within the past 3 years in biomarker research in MS, specifically highlighting recent advances in the validation of cerebrospinal fluid biomarkers such as neurofilaments (light and heavy chains), chitinases and chitinase 3-like proteins, soluble surface markers of innate immunity, and oligoclonal immunoglobulin M antibodies. Current research in circulating miRNAs as biomarkers of MS is also discussed. Continued validation and testing will be required before MS biomarkers are routinely applied in a clinical setting.</description><subject>Antibodies</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Care and treatment</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>FDA approval</subject><subject>Health aspects</subject><subject>Inflammation</subject><subject>MicroRNAs</subject><subject>Multiple sclerosis</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pathogenesis</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Review</subject><issn>1179-9900</issn><issn>1179-9900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt9rHCEQx6WkNCHNU9_LQiAEwl1GXVftQyBN-gtC8tD2WXZdvTNx9aK7hfz39bg0vSvVBwf9zHfGmUHoHYY5wTU_v769vZ5_l0LS5hU6wJjLmZQAe1v2PjrK-R7KYgJLyt-gfVpsoJwdIPLRxaFNDyblKtpqmPzoVt5UWXuTYnb5Q6WnlEwYK-tC78Iiv0WvbeuzOXo-D9HPz59-XH2d3dx9-XZ1eTPTNZfjrBWkb2jXkUabBkDYXrCOcS2s1RwkwaSmlje10bwjErqOY477BoOVPWjJ6SG62Oiupm4wvS45pNarVXIl4ScVW6d2X4JbqkX8pRpgFKQsAqfPAik-TiaPanBZG-_bYOKUFQEuGJdCkIIe_4PexymF8j1FCGENBwziL7VovVEu2Fji6rWoumQUcyZpTQs1_w9Vdm8Gp2Mw1pX7HYeTLYelaf24zNFPo4sh74JnG1CX1uRk7EsxMKj1OKj1OKjNOBT6_Xb9Xtg_zae_AZ2ErNc</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Harris, Violaine K</creator><creator>Tuddenham, John F</creator><creator>Sadiq, Saud A</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Biomarkers of multiple sclerosis: current findings</title><author>Harris, Violaine K ; Tuddenham, John F ; Sadiq, Saud A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-a82d63bb26ce6008fd85b57c8ffc70921243f764ec7b290bb7171d610f9d0c973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibodies</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Care and treatment</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>FDA approval</topic><topic>Health aspects</topic><topic>Inflammation</topic><topic>MicroRNAs</topic><topic>Multiple sclerosis</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pathogenesis</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harris, Violaine K</creatorcontrib><creatorcontrib>Tuddenham, John F</creatorcontrib><creatorcontrib>Sadiq, Saud A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Degenerative neurological and neuromuscular disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harris, Violaine K</au><au>Tuddenham, John F</au><au>Sadiq, Saud A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers of multiple sclerosis: current findings</atitle><jtitle>Degenerative neurological and neuromuscular disease</jtitle><addtitle>Degener Neurol Neuromuscul Dis</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>7</volume><spage>19</spage><epage>29</epage><pages>19-29</pages><issn>1179-9900</issn><eissn>1179-9900</eissn><abstract>Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is associated with chronic inflammation leading to demyelination and neurodegeneration. With the recent increase in the number of available therapies for MS, optimal treatment will be based on a personalized approach determined by an individual patient's prognosis and treatment risks. An integral part of such therapeutic decisions will be the use of molecular biomarkers to predict disability progression, monitor ongoing disease activity, and assess treatment response. This review describes current published findings within the past 3 years in biomarker research in MS, specifically highlighting recent advances in the validation of cerebrospinal fluid biomarkers such as neurofilaments (light and heavy chains), chitinases and chitinase 3-like proteins, soluble surface markers of innate immunity, and oligoclonal immunoglobulin M antibodies. Current research in circulating miRNAs as biomarkers of MS is also discussed. Continued validation and testing will be required before MS biomarkers are routinely applied in a clinical setting.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30050375</pmid><doi>10.2147/DNND.S98936</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-9900 |
| ispartof | Degenerative neurological and neuromuscular disease, 2017-01, Vol.7, p.19-29 |
| issn | 1179-9900 1179-9900 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6053099 |
| source | Dove Press Free; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies Biological markers Biomarkers Care and treatment Development and progression Diagnosis FDA approval Health aspects Inflammation MicroRNAs Multiple sclerosis NMR Nuclear magnetic resonance Pathogenesis Pathology Prognosis Proteins Review |
| title | Biomarkers of multiple sclerosis: current findings |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A04%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20of%20multiple%20sclerosis:%20current%20findings&rft.jtitle=Degenerative%20neurological%20and%20neuromuscular%20disease&rft.au=Harris,%20Violaine%20K&rft.date=2017-01-01&rft.volume=7&rft.spage=19&rft.epage=29&rft.pages=19-29&rft.issn=1179-9900&rft.eissn=1179-9900&rft_id=info:doi/10.2147/DNND.S98936&rft_dat=%3Cgale_pubme%3EA531759343%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2225670108&rft_id=info:pmid/30050375&rft_galeid=A531759343&rfr_iscdi=true |